Breast cancer
Conditions
Interventions
Case series:Anthracycline combined with cyclophosphamide sequential nab-paclitaxel or docetaxel
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Aged 18-70 years old, female; 2. The patients with primary breast cancer diagnosed by histopathology were stage II and stage III a [according to the TNM staging system of AJCC, 8th Edition 2017] after operation; 3. ECoG physical fitness score 0-1; 4. LVEF>=55%; 5. Bone marrow function: neutrophil >= 1.5 × 109 / L, platelet >= 100 × 109 / L, hemoglobin >= 90g / L; 6. Liver and kidney function: serum creatinine <= 1.5 times the upper limit of normal value; AST and alt <= 2.5 times the upper limit of normal value; total bilirubin <= 1.5 times the upper limit of normal value, or patients with Gilbert's syndrome <= 2.5 times the upper limit of normal value; 7. The patients have good compliance with the planned treatment, can understand the research process of this study and sign the written informed consent.
Exclusion criteria
Exclusion criteria: 1. Previously received cytotoxic chemotherapy, endocrine therapy, biological therapy or radiotherapy for any reason; 2. New York Heart Association (NYHA) rating of patients with heart disease above grade II (including grade II); 3. Patients with serious systemic infection or other serious diseases; 4. Patients who are known to be allergic or intolerant to chemotherapy drugs or their adjuvants; 5) in the past 5 years, there have been other malignant tumors, except the cured carcinoma in situ of cervix and skin cancer without melanoma; 6) pregnancy or lactation, as well as childbearing age patients who refuse to take appropriate contraceptive measures during the trial; 7) participated in other experimental studies within 30 days before the administration of the first study drug; 8) patients not suitable for the study were judged by the researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2-year disease free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival time;Safety; | — |
Countries
China
Contacts
Public ContactTing Luo
West China Hospital, Sichuan University
Outcome results
None listed